Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma

Our Bureau

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics’ AMTAGVI™ (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting. AMTAGVI is the first individualized Tumor Infiltrating Lymphocyte (TIL) therapy […]

Subscribe Now